The exercise price for subscription of warrants of series TO3A and TO3B in Scandinavian ChemoTech AB has been set at SEK 4.79 per share, the exercise period begins April 11

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES THAN SUCH MEASURES WHICH FOLLOWS FROM SWEDISH REGULATIONS.

Scandinavian ChemoTech AB (“Scandinavian ChemoTech” or the “Company”) completed a rights issue of units in October 2022. Each (1) unit of series A consisted of one (1) newly issued share of series A and one (1) warrant of series TO3A. Each (1) unit of series B consisted of one (1) newly issued share of series B and one (1) warrant of series TO3B. One (1) warrant of series TO3A entitles the holder to subscribe for one (1) new share of series A in the Company and one (1) warrant of series TO3B entitles the holder to subscribe for one (1) new share of series B in the Company. The exercise price for subscription of shares through the exercise of the warrants of series TO3A and TO3B has been set at 70 percent of the volume-weighted average price of the Company's share of series B on Nasdaq First North Growth Market during the measurement period which ran from and including March 23, 2023 up to and including April 5, 2023, however not higher than SEK 12.50 per share or lower than the quota value for the Company's shares. The volume-weighted average price of the Company's share of series B during the measurement period amounted to approximately SEK 6.85 and thus the exercise price is determined to SEK 4.79. The exercise period for warrants of series TO3A and TO3B runs from April 11, 2023 up to and including April 24, 2023.

If all warrants of series TO3A and TO3B are exercised, the Company will receive approximately SEK 11.4 million, before issue costs. In order for the warrants not to expire without value, it is required that the holder actively subscribes for shares no later than April 24, 2023, or alternatively sells the warrants no later than April 20, 2023. Please note that some trustees may close their registration earlier than April 24, 2023.

Summarized terms for the warrants of series TO3A and TO3B:

Exercise period: April 11, 2023 – April 24, 2023.

Exercise price: SEK 4.79 per share.

Issue size: 2,384,449 warrants divided into 328,333 warrants of series TO3A and 2,056,116 warrants of series TO3B. At full utilization 328,333 shares of series A and 2,056,116 shares of series B is issued, which provides approximately SEK 11.4 million to the Company, before issue costs.

Last day for trading warrants of series TO3A and TO3B: April 20, 2023.

Share capital and dilution: At full utilization, the share capital increases by SEK 1,192,224.50, from SEK 6,151,752.00 to SEK 7,343,976.50. The number of shares increases at full utilization by 2,384,449 shares (328,333 shares of series A and 2,056,116 shares of series B), from 12,303,504 shares to 14,687,953 shares (1,706,666 shares of series A and 12,981,287 shares of series B). The dilution at full utilization amounts to approximately 16.23 percent of the number of shares and 16.80 percent of the votes in the Company.

Note that the warrants of series TO3A and TO3B that are not exercised at the latest April 24, 2023, or sold at the latest April 20, 2023, will expire without value. For the warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants. Please note that some trustees may close their registration earlier than April 24, 2023.

Advisors

Mangold Fondkommission AB is the financial advisor and Moll Wendén Advokatbyrå is the legal advisor to the Company in connection with the exercise of warrants of series TO3A and TO3B.

For more information, please contact:

Mohan Frick, CEO

Tel: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Certified Adviser: Redeye AB, Tel: +46 (0)8 - 121 576 90

E-mail: certifiedadviser@redeye.se

Scandinavian ChemoTech AB

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology.

ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.

Important Information

Release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions according to law and people in those jurisdictions, in which this press release has been announced or distributed, should inform themselves of and follow such legal restrictions. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in ChemoTech in any jurisdiction.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended. The information in this press release may not be announced, published or distributed, directly or indirectly, in whole or in part, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, South Africa, South Korea or in any other jurisdiction where the announcement, publication or distribution of the information would not comply with applicable laws and regulations.